Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU – Get Free Report)’s stock price traded up 2.8% during mid-day trading on Friday. The stock traded as high as $11.50 and last traded at $11.30. Approximately 1,650 shares traded hands during trading, a decline of 65% from the average session volume of 4,762 shares. The stock had previously closed at $10.99.
Drugs Made in America Acquisition Stock Up 2.8%
The firm has a fifty day simple moving average of $10.89 and a two-hundred day simple moving average of $10.80.
Drugs Made in America Acquisition Company Profile
Drugs Made in America Acquisition Corp. is a special purpose acquisition company (SPAC) formed to identify and complete a business combination with one or more operating businesses. Its Nasdaq-listed units trade under the symbol DMAAU.
The company does not have an established portfolio of drugs, medical products, or commercial services of its own. Its stated strategy is to pursue a merger, acquisition, or similar transaction with a company in the pharmaceutical, biotechnology, or related healthcare sectors, with an emphasis on businesses connected to drug development or manufacturing in the United States.
As a SPAC, Drugs Made in America Acquisition Corp.
Recommended Stories
- Five stocks we like better than Drugs Made in America Acquisition
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Drugs Made in America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made in America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
